重组人凝血因子Ⅶa治疗血液病患者出血的临床疗效分析
回顾性分析31例血液病患者共38次出血使用重组人凝血因子Ⅶa(rFⅦa)的疗效,获得性血友病A/血友病伴抑制物、急性早幼粒细胞白血病、急性非急性早幼粒细胞白血病患者出血的总体有效率分别为90%(9/10)、71.4%(5/7)、60.0%(3/5),高于造血干细胞移植后患者(30.8%);出血评分2分者有效率(100.0%)高于3分(66.7%)及4分(51.6%)。结论认为rFⅦa止血疗效受疾病类型、出血部位及严重程度等多因素影响,出血早期使用对疗效至关重要,止血同时应积极治疗基础疾病。
要点
- rFⅦa对获得性血友病A/血友病伴抑制物出血有效率90%(9/10),高于移植后患者30.8%。
- 出血评分2分者rFⅦa有效率100.0%,高于3分66.7%及4分51.6%。
- 颅内出血rFⅦa有效率25.0%(2/5),血尿66.7%(6/9),消化道出血41.7%(5/12)。
核心结论
- rFⅦa止血疗效受疾病类型、出血部位及出血评分等多因素影响。
- rFⅦa对获得性血友病A/血友病伴抑制物及急性白血病患者出血疗效较好,对造血干细胞移植后患者出血疗效欠佳。
- 出血早期使用rFⅦa对止血治疗成功至关重要,止血同时应积极治疗基础疾病。
研究设计与样本
- 回顾性分析31例血液病患者共38次出血使用rFⅦa治疗的临床资料。
主要发现
- 获得性血友病A/血友病伴抑制物出血rFⅦa有效率90%(9/10),急性早幼粒细胞白血病71.4%(5/7),急性非急性早幼粒细胞白血病60.0%(3/5),均高于造血干细胞移植后患者30.8%。
- 出血评分2分者rFⅦa有效率100.0%,高于3分66.7%及4分51.6%。
- 颅内出血rFⅦa有效率25.0%(2/5),血尿66.7%(6/9),消化道出血41.7%(5/12)。
- 3例次关节及肌肉出血和5例次皮肤、鼻黏膜、咽部及齿龈出血疗效均为极好。
- 移植后患者出血评分4分时,高剂量及多次使用rFⅦa不一定取得好的疗效;获得性血友病A/血友病伴抑制物及急性白血病患者出血评分4分时,低剂量rFⅦa能取得好的疗效,但最低剂量(22.5 μg/kg)疗效差。
临床怎么用
- 作者认为出血早期使用rFⅦa对止血治疗成功至关重要,止血治疗同时应积极治疗基础疾病。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the treatment efficacy of recombinant activated factor Ⅶ (rFⅦa) for bleeding among patients with hematologic disorders. Methods: A total of 38 times of bleeding in 31 patients with hematological disease treated with rFⅦa were analyzed retrospectively. Results: The clinical effective rate of rFⅦa for bleeding management in acquired hemophilia A (AHA) patients/hemophilia patients with inhibitor, acute promyelocytic leukemia (APL) patients and patients with non-APL leukemia was 90% (9/10) , 71.4% (5/7) and 60.0% (3/5) , respectively, which was higher than that in patients following HSCT (30.8%) . The clinical effective rate of rFⅦa for patients with bleeding score of 2 (100.0%) was higher than that with 3 (66.7%) and 4 (54.1%) . The effective rate of rFⅦa was 25.0% (2/5) in 5 patients with cerebral hemorrhage, 66.7% (6/9) in 9 patients with hematuria and 41.7% in 12 patients with gastrointestinal hemorrhage. The curative effect for 3 patients with joints and muscle bleeding and 5 patients with skin, nasal, pharyngeal and gum bleeding was excellent. Following HSCT, among patients with bleeding score of 4 points, high dose and repeated use of rFⅦa did not necessarily achieve a good effect. Among AHA/hemophilia patients with inhibitors and patients with acute leukemia who had bleeding score of 4 points, the use of low dose FⅦa could achieve good therapeutic effect, however the efficacy of lowest dose (22.5 μg/kg) rFⅦa was poor. Conclusions: The hemostasis efficacy of rFⅦa is affected by various factors such as diseases, bleeding sites, bleeding score and so on. The use of rFⅦa can achieve good efficacy for bleeding management in AHA patients/hemophilia patients with inhibitor, APL patients and patients with non-APL leukemia. However the efficacy of rFⅦa for bleeding of patients after HSCT is poor. Early use of rFⅦa is important for successful hemostatic treatment. Management of underlying condition is as important as hemostatic treatment. 目的: 研究重组人凝血因子Ⅶa(rFⅦa)治疗血液病患者出血的疗效。 方法: 回顾性分析rFⅦa治疗31例血液病患者共38次出血的临床资料。 结果: rFⅦa治疗获得性血友病A(AHA)/血友病伴抑制物、急性早幼粒细胞白血病(APL)、急性非APL白血病患者出血的总体有效率分别为90%(9/10)、71.4%(5/7)、60.0%(3/5),高于造血干细胞移植后患者(30.8%);rFⅦa治疗评分为2分出血的有效率(100.0%)高于3分(66.7%)及4分(51.6%)出血;5例次颅内出血中2例次(25.0%)有效;9例次血尿中6例次(66.7%)有效;12例次消化道出血中5例次(41.7%)有效。3例次关节及肌肉出血的疗效均为极好,5例次出血部位为皮肤、鼻黏膜、咽部及齿龈,疗效均为极好;移植后患者在出血评分为4分时,高剂量以及多次使用rFⅦa并不一定能取得好的疗效。AHA/血友病伴抑制物及急性白血病患者合并的出血,在评分为4分时,使用低剂量rFⅦa能取得好的疗效,但最低用药剂量(22.5 μg/kg)的疗效差。 结论: rFⅦa的止血疗效受疾病类型、出血部位以及严重程度等多个因素的影响。rFⅦa对AHA/血友病伴抑制物以及急性白血病患者的出血具有较好的疗效,但对移植后患者的出血疗效欠佳。出血早期使用rFⅦa对于疗效至关重要。在止血治疗的同时,应积极治疗基础疾病。.
引用
- Liu W, Xue F, Liu XF, et al. [Analysis of clinical efficacy of recombinant activated factor Ⅶ on bleeding in patients with hematologic disorders]. Zhonghua Xue Ye Xue Za Zhi. 2017. PMID: 28565741. doi:10.3760/cma.j.issn.0253-2727.2017.05.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。